BRIVIACT

Peak

brivaracetam

NDAORALTABLET
Approved
Feb 2016
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Mechanism of Action

Epoxide Hydrolase Inhibitors

Clinical Trials (5)

NCT06315322Phase 3Recruiting

A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Started Jul 2024
120 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
NCT06312566Phase 1Completed

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants

Started Mar 2024
64 enrolled
Healthy Study Participants
NCT05315947Phase 1Completed

A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants

Started Apr 2022
24 enrolled
Healthy Study Participants
NCT05109234Phase 3Completed

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Started Mar 2022
84 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy
NCT04666610Phase 3Active Not Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Started Jul 2021
153 enrolled
Childhood Absence EpilepsyJuvenile Absence Epilepsy

Loss of Exclusivity

LOE Date
Apr 9, 2030
49 months away
Patent Expiry
Apr 9, 2030

Patent Records (2)

Patent #ExpiryTypeUse Code
6911461
Feb 21, 2026Expired
SubstanceProduct
U-2295
10729653
Apr 9, 2030
Product